Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.84 |
| ▸ | HTR2C | P28335 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TSPO | P30536 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9472878 | 0.92 | OPRK1 (0.76) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL29642025 | 0.92 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL11658148 | 0.92 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL18472 | 0.92 | OPRK1 (1.00) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| Medazepam SCHEMBL78352 | 0.90 | OPRK1 (0.97) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL3235774 | 0.90 | OPRK1 (0.73) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL9472170 | 0.83 | OPRK1 (0.75) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL11680057 | 0.83 | OPRK1 (0.76) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL2921949 | 0.81 | OPRK1 (0.60) | OPRK1PDE4DNR1I2ADORA3HTR2C | |
| SCHEMBL11682597 | 0.80 | OPRK1 (0.67) | OPRK1PDE4DNR1I2ADORA3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8323621-B2 | site-directed delivery of contrast agent; brain or breast cancer; 1,4,7,10 tetraazacyclododecane having variable chelating ions, phosphoester chains, and light harvesting moieties for changing imaging methods; conjugated to high affinity PBR ligand PK11195; bound to a PVA or a PEG delivery vehicle | VANDERBILT UNIVERSITY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | BORNHOP DARRYL J | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | VANDERBILT UNIVERSITY | 2008-10-02 | — | — | US | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338651-B2 | Multi-use multimodal imaging chelates | TEXAS TECH UNIVERSITY SYSTEM (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241074-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | OPRK1 2697/4885PDE4D 3936/4885NR1I2 2345/4885 |
| US-20080241873-A1 | MULTI-USE MULTIMODAL IMAGING CHELATES | PCNA, CLTC, CLTB | OPRK1 2697/4885PDE4D 3936/4885NR1I2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.